Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patients' subjective assessment as a decisive predictor of malignancy in pelvic masses: results of a multicentric, prospective pelvic mass study.
Koch E, Torsten U, Mecke H, Richter R, Hellmeyer L, Nohe G, Müller B, Boeneß-Zaloum J, Ames K, Chen F, Beteta C, Hasenbein K, Pirmorady A, Zimmermann M, Dimitrova D, Tauber R, Sehouli J, Knieper CL, Ioana Braicu E. Koch E, et al. Among authors: dimitrova d. J Psychosom Obstet Gynaecol. 2022 Sep;43(3):273-278. doi: 10.1080/0167482X.2020.1850684. Epub 2020 Nov 30. J Psychosom Obstet Gynaecol. 2022. PMID: 33252280
Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
Dimitrova D, Ruscito I, Olek S, Richter R, Hellwag A, Türbachova I, Woopen H, Baron U, Braicu EI, Sehouli J. Dimitrova D, et al. Tumour Biol. 2016 Sep;37(9):12329-12337. doi: 10.1007/s13277-016-5109-8. Epub 2016 Jun 14. Tumour Biol. 2016. PMID: 27297669
A phase III, open label, randomized multicenter controlled trial of oral versus intravenous treosulfan in heavily pretreated recurrent ovarian cancer: a study of the North-Eastern German Society of Gynecological Oncology (NOGGO).
Sehouli J, Tomè O, Dimitrova D, Camara O, Runnebaum IB, Tessen HW, Rautenberg B, Chekerov R, Muallem MZ, Lux MP, Trarbach T, Gitsch G. Sehouli J, et al. Among authors: dimitrova d. J Cancer Res Clin Oncol. 2017 Mar;143(3):541-550. doi: 10.1007/s00432-016-2307-0. Epub 2016 Nov 28. J Cancer Res Clin Oncol. 2017. PMID: 27896440 Free PMC article. Clinical Trial.
Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
Sun T, Ruscito I, Dimitrova D, Chekerov R, Kulbe H, Baron U, Blanchard V, Panici PB, Darb-Esfahani S, Sehouli J, Olek S, Braicu EI. Sun T, et al. Among authors: dimitrova d. Int J Gynecol Cancer. 2017 Oct;27(8):1658-1665. doi: 10.1097/IGC.0000000000001071. Int J Gynecol Cancer. 2017. PMID: 28691938
Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany.
Dimitrova D, Naghavi B, Richter R, Nasser S, Chekerov R, Braicu EI, David M, Blohmer J, Inci G, Torsten U, Oskay-Özcelik G, Blau I, Fersis N, Holzgreve A, Keil E, Keller M, Keilholz U, Sehouli J. Dimitrova D, et al. BMC Cancer. 2021 Sep 12;21(1):1018. doi: 10.1186/s12885-021-08731-6. BMC Cancer. 2021. PMID: 34511112 Free PMC article.
279 results